
J&J charts $2.58-B course
Johnson & Johnson is partnering with Sail Biomedicines to advance in vivo CAR-T treatments for immune-mediated diseases, with an exclusive $2.58 billion…
· 1 MIN READ
Topic
Latest Daily Tribune news and analysis on Mitch Johnson.